Novartis to Acquire Regulus Therapeutics for ~$1.7B

Shots: Novartis to acquire Regulus Therapeutics incl. its lead asset, farabursen via its wholly owned subsidiary, which will merge with Regulus upon closing, resulting in Regulus becoming an indirect wholly owned subsidiary of Novartis As per the deal, Regulus will get ~$0.8B upfront, with shareholders receiving $7/share in cash, & ~$0.9B upon achievement of a…

ByRidhi RastogiMay 1, 2025

News

Merck KGaA to Acquire SpringWorks Therapeutics for ~$3.9B

Shots: Merck KGaA has entered into a definitive agreement to acquire SpringWorks Therapeutics to strengthen its rare disease portfolio & expand SpringWorks’ reach to markets beyond the US As per the agreement, Merck KGaA will acquire SpringWorks for $47/share (~26% premium), with an equity value of ~$3.9B or an enterprise value of ~$3.4B, funded by…

ByRidhi RastogiApril 28, 2025

News

VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies

Shots: VERAXA to reverse merge with Voyager, where the combined entity- "VERAXA Biotech” will be listed on Nasdaq under VERX ticker; closing expected in Q4’25 As per the deal, VERAXA will have access to ~$253M cash from Voyager’s trust at closing & contribute ~$1.3B in equity for ~130M shares, with all shareholders rolling over 100%…

ByRidhi RastogiApril 23, 2025

News

Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake

Shots: Alumis and ACELYRIN have amended their 2025 merger agreement, which originally granted ACELYRIN stockholders 0.4274 Alumis shares/share, giving them a 45% stake in the combined company As per the amendment, ACELYRIN stockholders will receive 0.4814 Alumis shares/share, allowing them to own 48% of the combined entity on a fully diluted basis; closing expected in Q2'25…

ByRidhi RastogiApril 22, 2025

News

RadNet to Acquire iCAD for ~$103M

Shots: RadNet has entered into a definitive merger agreement to acquire iCAD in an all-stock transaction, through which iCAD will become a wholly owned subsidiary of RadNet As per the deal, iCAD stockholders will receive 0.0677 RadNet shares/ iCAD share, representing transaction value of ~$103M, or ~$3.61/share (~98% premium) on a fully diluted basis; closing…

ByRidhi RastogiApril 16, 2025

News

Intas Pharmaceuticals Acquires Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)

Shots: Intas has acquired Coherus’ Udenyca business (incl. prefilled syringe, autoinjector & on-body injector), a biosimilar version of Amgen’s Neulasta (pegfilgrastim) via 2024 asset purchase agreement; Accord BioPharma (Intas’ US specialty division) will handle Udenyca’s US business As per the deal, Coherus received $483.4M upfront in cash, incl. $118.4M for Udenyca inventory, with an additional…

ByRidhi RastogiApril 15, 2025

News

Siemens to Acquire Dotmatics for $5.1B, Strengthening its Position in Life Science Market

Shots: Siemens has entered into an agreement to acquire Dotmatics for $5.1B from Insight Partners, strengthening its position in the life science market Acquisition will integrate Siemens' manufacturing, industrial simulation, & AI expertise with Dotmatics' complementary offerings, creating an AI-powered product lifecycle management (PLM) portfolio as part of Siemens Xcelerator for seamless R&D-to-manufacturing connectivity Siemens will…

ByRidhi RastogiApril 3, 2025

News

Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock

Shots: Mallinckrodt & Endo to combine their generic pharmaceuticals & Endo’s sterile injectables businesses, later separating the unit, with combined company headquartered in Dublin, Ireland & Endo operating as Mallinckrodt’s subsidiary As per the deal, Endo shareholders will receive $80M in cash & own 49.9% of the combined company, while Mallinckrodt shareholders will hold 50.1%,…

ByRidhi RastogiMarch 18, 2025

News

AstraZeneca to acquire EsoBiotec for ~$1B

Shots: AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing…

ByRidhi RastogiMarch 18, 2025

News

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M

Shots: Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25 As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in…

ByRidhi RastogiMarch 10, 2025

Novartis to Acquire Regulus Therapeutics for ~$1.7B

Merck KGaA to Acquire SpringWorks Therapeutics for ~$3.9B

VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies

Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake

RadNet to Acquire iCAD for ~$103M

Intas Pharmaceuticals Acquires Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)

Siemens to Acquire Dotmatics for $5.1B, Strengthening its Position in Life Science Market

Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock

AstraZeneca to acquire EsoBiotec for ~$1B

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter